ORIGINAL ARTICLE

Radiographical findings in patients with liver cirrhosis and hepatic encephalopathy

Saleh Elwir1,*, Hassan Hal2, Joshua Veith3, Ian Schreibman4, Zakiyah Kadry5 and Thomas Riley4

1Department of Internal Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania (PA), USA, 2Department of Radiology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA, 3Penn State Milton S. Hershey Medical Center and School of Medicine, Hershey, PA, USA, 4Division of Gastroenterology and Hepatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA and 5Division of Transplant Surgery, Penn State Milton S. Hershey Medical Center, Hershey PA, USA

*Corresponding author. Division of Gastroenterology, Hepatology & Nutrition, University of Minnesota, 406 Harvard Street SE, MMC 36, Minneapolis, MN 55455, USA. Tel: +1-612-626-0419; Fax: +1-612-625-5620; Email: elwir001@umn.edu

Abstract

Background and aims: Hepatic encephalopathy is a common complication encountered in patients with liver cirrhosis. Hepatic encephalopathy is not reflected in the current liver transplant allocation system. Correlation was sought between hepatic encephalopathy with findings detected on radiographic imaging studies and the patient’s clinical profile.

Methods: A retrospective analysis was conducted of patients with cirrhosis, who presented for liver transplant evaluation in 2009 and 2010. Patients with hepatocellular carcinoma, ejection fraction less than 60% and who had a TIPS (transjugular intrahepatic portosystemic shunting) procedure or who did not complete the evaluation were excluded. Statistical analysis was performed and variables found to be significant on univariate analysis (P < 0.05) were analysed by a multivariate logistic regression model.

Results: A total of 117 patients met the inclusion criteria and were divided into a hepatic encephalopathy group (n = 58) and a control group (n = 59). Univariate analysis found that a smaller portal vein diameter, smaller liver antero-posterior diameter, liver nodularity and use of diuretics or centrally acting medications showed significant correlation with hepatic encephalopathy. This association was confirmed for smaller portal vein, use of diuretics and centrally acting medications in the multivariate analysis.

Conclusion: A decrease in portal vein diameter was associated with increased risk of encephalopathy. Identifying patients with smaller portal vein diameter may warrant screening for encephalopathy by more advanced psychometric testing, and more aggressive control of constipation and other factors that may precipitate encephalopathy.

Key words: hepatic encephalopathy; cirrhosis; portal vein diameter; computed tomography (CT)

Introduction

Cirrhosis is associated with multiple hemodynamic changes that can be assessed by invasive (transjugular pressure measurement) and non-invasive means (liver duplex) [1]. Through the transjugular route, portal venous pressure gradients can be measured and a measurement exceeding 5 mm Hg

Submitted: 18 June 2015; Revised: 13 August 2015; Accepted: 23 August 2015

© The Author(s) 2015. Published by Oxford University Press and the Digestive Science Publishing Co. Limited. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
is diagnostic of portal hypertension [2]. Duplex studies can detect the presence or absence of portal vein thrombosis and assess the diameter, flow rate and direction of portal venous flow [3].

Doppler ultrasound is a valuable non-invasive tool in the evaluation of the hemodynamics of patients with cirrhosis and portal hypertension. Hepatic artery pulsatility index (peak systolic velocity minus end diastolic velocity, divided by the mean velocity) correlated directly with portal venous pressure gradient [4]. Hepatic venous flow pattern is another parameter that was investigated in patients with cirrhosis. The changes in hepatic venous waveforms correlated with the extent of hepatic fibrosis. Certain waveforms were associated with poorer prognosis and lower five-year survival, even among patients with the same Child-Pugh score [5].

Hepatic encephalopathy (HE) is a frequent complication and one of the most debilitating manifestations of liver disease, severely affecting the lives of patients and their care providers [6]; it is also associated with increased mortality [7]. HE encompasses a broad range of neuropsychiatric deficits, from clinically undetectable abnormalities, which are only apparent on psychiatric evaluation, to confusion, coma and death [8]. Although increased levels of serum ammonia are thought to play a key role in the pathophysiology of HE, the diagnosis of this entity remains a clinical process [9]. Psychometric and neuropsychological testing are available and may be used for the evaluation of patients with suspected minimal or covert HE. The tests require experienced professionals to administer them and are time-consuming. Also, none of the available tests are specific for HE, especially if confounding factors—such as neuropsychiatric disorders, psychoactive medication, or current alcohol use—are present [6]. The most recent clinical guidelines by the American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) state that an operational approach may be to test patients who have problems with their quality of life, or in whom there are complaints from the patients and their relatives [5].

In this study we reviewed imaging studies [computed tomography (CT)/magnetic resonance imaging (MRI) and Liver duplex ultrasound] in patients with liver cirrhosis, who were evaluated for liver transplantation. We planned on assessing whether any of the findings detected in the aforementioned studies had any correlation with HE that could predict or explain the patients’ clinical status.

**Patients and methods**

In the period between 1 January 2009 and 31 December 2010, 252 patients were evaluated in the liver transplant clinic at Penn State Milton S. Hershey Medical Center. Patients with hepatocellular carcinoma (HCC) (n = 52), ejection fraction less than 60% (n = 7), those who had a TIPS (transjugular intrahepatic portosystemic shunting) procedure (n = 6) and patients who did not complete the evaluation (n = 70) were excluded from the analysis; patients with fulminant liver failure were also not included in the analysis. These patients were excluded because HE is a known complication encountered in patients who undergo TIPS procedure and patients with low ejection fraction may have altered hemodynamics that may present in a fashion similar to portal hypertension. Patients with HCC are usually referred to a transplant clinic early in the course of their disease and they frequently have HCC as the only manifestation of their liver disease. Patients with portal vein thrombosis were not excluded from this analysis, in order to assess any contribution it may make to HE.

All imaging studies were made within three months of the evaluation date. Liver duplexes, abdominal CT scans and MRIs of these patients were reviewed by one attending radiologist, who was blinded to the clinical information. Liver anteroposterior and crano-caudal diameters were measured from the right hepatic lobe. The largest spleen diameter (whether anteroposterior or crano-caudal) was measured. Portal vein diameter was assessed at the porta hepatis by CT scan (Figure 1). Given that the timing of the measurement of the portal vein in relation to respiration could not be confirmed in this retrospective study, only measurements of the portal vein by CT/MRI were used. Resistive Index (RI), measured by duplex ultrasonography, was calculated by the following equation:

\[
RI = \frac{\text{peak systolic velocity} - \text{end diastolic velocity}}{\text{peak systolic velocity}} \times 100
\]

Parasophageal, splenorenal varices and umbilical vein re-canalization were reported if the CT scan imaging showed any evidence of their presence, regardless of size.

One hundred and seventeen patients were included in the study. They were divided into an HE group (n = 58) and a control group (n = 59) based on whether or not they exhibited clinical evidence of HE. Patients were included in the HE group if they had a current or previous diagnosis of Grade 2 or higher HE according to the West Haven criteria [10]. The findings of the imaging studies, clinical and laboratory data were compared between the two groups. The study was approved by the Penn State Milton S. Hershey Medical Center Institutional Review Board in September 2011.

**Statistical analysis**

Univariate analysis was carried out with chi-squared tests for binomial variables and analysis of variance (ANOVA) for continuous variables. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for selected variables that were identified as significant in the univariate analysis. The concordance index (c-index) was also reported. Selected variables were evaluated by a multivariate logistical regression model. A P-value of less than 0.05 was considered significant.

![Figure 1. CT scan of the abdomen showing large paraesophageal varices. In this patient, portal vein diameter was measured at 8 mm.](image-url)
Results

Patient population

The most common causes of cirrhosis in this cohort were alcohol (18%), hepatitis C virus (HCV) (21%) and a combination of HCV and alcohol (21%). The HE and control groups were comparable in terms of age, sex, race and model for end-stage liver disease (MELD) scores (Table 1).

When correlating the patients’ historical data and medication profiles to their presentation, patients using centrally acting medications (antidepressants, sleep aids, benzodiazepines or antipsychotics) were more likely to have HE (P = 0.002). Patients with HE were more likely than the controls to be on diuretics (P = 0.002) (Table 2).

Imaging studies

CT scan of the abdomen revealed that patients in the HE group had nodular liver counters and had smaller liver antero-posterior diameters (P = 0.018 and P = 0.001, respectively). Spleen dimensions and the presence of paraesophageal shunts, splenorenal shunts, umbilical vein recanalization, caudate lobe hypertrophy, liver cranio-caudal diameter did not have any association with the presence or absence of encephalopathy. Liver duplex ultrasound studies did not demonstrate any association between portal venous flow velocities, direction of flow or hepatic artery resistive indices with a patient’s presentation (Table 2).

Mean portal vein diameter was 12.1 ± 2.9 mm in the HE group, as compared with 14.0 ± 3.1 mm in the control group (P = 0.001). The association between smaller portal vein size and HE was most pronounced when a portal vein diameter of 12 mm was used as a cut-off value (Figure 2). Two patients in the control group and 1 patient in the HE group had portal vein thrombosis and accurate assessment of portal vein size, velocity and flow direction were not possible.

Multivariate analysis

Variables that were found to significantly correlate with HE were included in a multivariate logistical regression model. Portal vein diameter and the use of centrally acting medications and diuretics are significant predictors of encephalopathy in this multivariate model. None of the other factors was significant (Table 3).

When the data on the patients with larger portal vein diameter (>12 mm) was compared with patients with smaller portal vein diameter (≤12 mm), the average MELD in the smaller portal vein group was 13.8 ± 4.9, as compared with 12.9 ± 4.2 in the patients with the larger portal vein diameter (P = 0.29). Twenty-three percent of patients with smaller portal vein diameter had reversed portal flow, compared with just 3% in patients with larger portal vein (P = 0.002). Thirty-three percent of patients with smaller portal veins had a portal venous flow velocity of less than 16 cm/s, compared with 17% in the patients with larger portal vein diameter (P = 0.043). Although patients with smaller portal vein diameters were observed to have smaller liver and spleen dimensions and higher prevalence of shunts, the associations were not statistically significant. There was no significant difference in the use of beta blockers among patients with larger and smaller portal vein diameter (P = 0.21) (Table 4).

---

### Table 1. Baseline characteristics of the study population

| Variable                      | HE group (n = 58) | Control group (n = 59) | P-value |
|-------------------------------|------------------|------------------------|---------|
| Age (years)                   | 54.6 ± 8.8       | 54.3 ± 10.6            | >0.05   |
| Female gender                 | 24 (41.4)        | 16 (27.1)              | >0.05   |
| Body mass index               | 29.9 ± 6.1       | 28.3 ± 6.2             | >0.05   |
| MELD score                    | 13.9 ± 5.0       | 12.7 ± 4.1             | >0.05   |
| Etiology of cirrhosis         |                  |                        | >0.05   |
| Alcohol                       | 10 (17%)         | 11 (19%)               |         |
| HCV                           | 16 (28%)         | 9 (15%)                |         |
| Alcohol + HCV                 | 14 (24%)         | 10 (17%)               |         |
| PSC                           | 2 (3%)           | 9 (15%)                |         |
| NASH                          | 9 (16%)          | 8 (14%)                |         |
| Othera                        | 7 (12%)          | 12 (20%)               |         |

Data expressed as mean ± standard deviation or number (%).

HE = hepatic encephalopathy; HCV = hepatitis C virus; MELD = model for end-stage liver disease; NASH = non-alcoholic steatohepatitis; PSC = primary sclerosing cholangitis

*aOthers include 2 PBC (primary biliary cirrhosis), 1 cryptogenic, 1 HBV (hepatitis B virus), 1 hemochromatosis, 1 Wilson, and 1 autoimmune hepatitis in the HE group, and 3 PBC, 3 cryptogenic, 2 HBV, 2 autoimmune hepatitis, 1 hemochromatosis and 1 alpha one antitrypsin deficiency in the control group.

### Table 2. Correlation of various historical data, laboratory test results and imaging values with HE

| Variable                              | HE group (n = 58) | Control group (n = 59) | P-value |
|---------------------------------------|------------------|------------------------|---------|
| **Historical information**            |                  |                        |         |
| Esophageal varices                    | 60%              | 66%                    | 0.518   |
| Variceal bleeding                     | 21%              | 24%                    | 0.693   |
| Variceal band ligation                | 24%              | 24%                    | 0.952   |
| **Medications**                       |                  |                        |         |
| Non-selective beta blockers           | 36%              | 44%                    | 0.386   |
| Narcotics                             | 14%              | 8%                     | 0.394   |
| Centrally acting medicationsa         | 41%              | 15%                    | 0.002   |
| Diureticsb                            | 88%              | 65%                    | 0.002   |
| **Laboratory tests**                  |                  |                        |         |
| Na <135 mmol/L                        | 69%              | 68%                    | 0.892   |
| Creatinine > 1 mg/dL                  | 31%              | 29%                    | 0.793   |
| **CT scan findings**                  |                  |                        |         |
| Liver antero-posterior diameter ≤6 cm | 91%              | 68%                    | 0.001   |
| Liver cranio-caudal diameter ≤16 cm   | 69%              | 58%                    | 0.203   |
| Spleen diameter ≥16 cm                | 47%              | 53%                    | 0.517   |
| Nodular liver                         | 86%              | 68%                    | 0.018   |
| Caudate lobe hypertrophy              | 55%              | 64%                    | 0.308   |
| Paraesophageal varices                | 67%              | 63%                    | 0.608   |
| Splenorenal varices                   | 72%              | 83%                    | 0.166   |
| Umbilical vein recanalization         | 60%              | 58%                    | 0.765   |
| Presence of ascites                   | 55%              | 49%                    | 0.515   |
| Portal vein diameter ≤12 mm           | 58%              | 28%                    | 0.001   |
| **Duplex ultrasound findings**        |                  |                        |         |
| Portal vein flow velocity <16 cm/s    | 26%              | 20%                    | 0.475   |
| Hepatofugal flow                      | 16%              | 7%                     | 0.132   |
| Hepatic artery resistive index ≥0.75  | 33%              | 39%                    | 0.527   |

*aCentrally acting medications include antidepressants, benzodiazepines, sleep aids, and antipsychotics.

*bDiuretics include loop diuretics, thiazides, and spironolactone.
Higher incidence of hepatofugal flow, higher incidence of HE patients with smaller portal veins had slower portal vein flow, associated with an increased risk of encephalopathy [17, 18, 21]. Large collateral shunts, reversed flow, those with a slower flow and in those patients noted in patients with liver cirrhosis, who had a hepatofugal or not possible with the current study design. We hypothesize that monitoring the diameter and hemodynamics of the portal vein over time may offer non-invasive clues that can point to the advancement of liver disease and possibly predict the onset of complications related to this, such as HE. This correlation would need validation in prospective trials.

The limitations of this study include its retrospective nature, small sample size and the use of clinical parameters for diagnosis of encephalopathy. It is possible that some of the patients in the control group had minimal encephalopathy that could only be diagnosed with psychometric testing. Quantification of the degree of shunting was not possible with the current study design. It was also noted that a higher proportion of patients in the HE group were on diuretics and centrally acting medications (antidepressants, benzodiazepines, hypnotics and antipsychotics). Whether the HE caused these patients to have sleep disturbances, depressive or psychological symptoms or the medications themselves caused the HE symptoms could not be assessed by our study design. With regard to the use of diuretics, dehydration and electrolyte disturbances are known to exacerbate HE. The effect that the use of diuretics had on the volume status of these patients could not be assessed by our study design. Whether the HE caused these patients to have sleep disturbances, depressive or psychological symptoms or the medications themselves caused the HE symptoms could not be assessed by our study design.

In conclusion, smaller portal vein diameter and the use of certain medications correlated with the presence of HE. In patients with liver cirrhosis, monitoring the portal vein diameter over time may identify patients whose disease has progressed and who are at risk of HE. A decrease in portal vein diameter over time may warrant screening for HE by more advanced therapies.

### Table 4. Correlation between portal vein size and various radiographical parameters

| Variable                  | PV ≤ 12 | PV > 12 | P-value |
|---------------------------|---------|---------|---------|
| **CT scan findings**      |         |         |         |
| Liver antero-posterior diameter ≤ 16 cm | 90%    | 74%    | 0.053   |
| Liver cranio-caudal diameter ≤ 16 cm | 65%    | 63%    | 0.8     |
| Spleen diameter ≥ 16 cm   | 39%    | 55%    | 0.08    |
| Nodular liver             | 75%    | 78%    | 0.71    |
| Caudate lobe hypertrophy  | 59%    | 60%    | 0.93    |
| Paurasophageal varices     | 71%    | 60%    | 0.2     |
| Splenorenal varices        | 84%    | 74%    | 0.2     |
| Umbilical vein recanalization | 61%  | 60%    | 0.89    |
| Presence of ascites        | 49%    | 55%    | 0.49    |
| **Duplex ultrasound findings** |       |         |         |
| Portal vein flow velocity < 16 cm/s | 33%    | 17%    | 0.043   |
| Hepatofugal flow           | 23%    | 3%     | 0.002   |
| Hepatic artery resistive index ≥ 0.75 | 39%    | 33%    | 0.51    |

Discussion

The diameter and hemodynamics of the portal vein change with the advancement of cirrhosis [11]. The diameter of the portal vein is a reflection of the degree of the resistance it faces in the liver and the velocity of bloodflow within the portal vein. A normal portal vein diameter is considered to be around 10 mm [12]. Studies have shown that this value increases with the advancement of liver fibrosis and subsequently with the development of cirrhosis, where the mean portal vein diameter is reported to be around 14 mm [13–15]. A smaller portal vein was noted in patients with liver cirrhosis, who had a hepatofugal or reversed flow, those with a slower flow and in those patients with large collateral vessels [16–20]. Large collateral shunts, hepatofugal flow and slower flow were all found to be associated with an increased risk of encephalopathy [17, 18, 21].

Some of these correlations were confirmed in our analysis. Patients with smaller portal veins had slower portal vein flow, higher incidence of hepatofugal flow, higher incidence of HE and a higher prevalence of portosystemic shunts (the latter not being statistically significant). The smaller portal vein diameter observed in our study is most probably a reflection of the hemodynamic changes that occur with the advancement of cirrhosis and portal hypertension. As the resistance within the liver increases, the portal pressure and consequently the portal vein diameter will increase. With the increase in portal pressure, portosystemic shunts form, diverting blood away from the portal circulation to the systemic circulation. With time, the decrease in blood flow in the portal vein may be reflected in a smaller portal vein. With the advancement of cirrhosis, the liver’s ability to detoxify blood decreases and as a result patients will have higher incidence of HE. Changes in portal hemodynamics and the development of HE are both manifestations of advancing liver disease; the correlation between these two entities was noted in our study. We hypothesize that monitoring the diameter and hemodynamics of the portal vein over time may offer non-invasive clues that can point to the advance of liver disease and possibly predict the onset of complications related to this, such as HE. This correlation would need validation in prospective trials.

The limitations of this study include its retrospective nature, small sample size and the use of clinical parameters for diagnosis of encephalopathy. It is possible that some of the patients in the control group had minimal encephalopathy that could only be diagnosed with psychometric testing. Quantification of the degree of shunting was not possible with the current study design. It was also noted that a higher proportion of patients in the HE group were on diuretics and centrally acting medications (antidepressants, benzodiazepines, hypnotics and antipsychotics). Whether the HE caused these patients to have sleep disturbances, depressive or psychological symptoms or the medications themselves caused the HE symptoms could not be assessed by our study design. With regard to the use of diuretics, dehydration and electrolyte disturbances are known to exacerbate HE. The effect that the use of diuretics had on the volume status of these patients could not be assessed by our study design.

In conclusion, smaller portal vein diameter and the use of certain medications correlated with the presence of HE. In patients with liver cirrhosis, monitoring the portal vein diameter over time may identify patients whose disease has progressed and who are at risk of HE. A decrease in portal vein diameter over time may warrant screening for HE by more advanced therapies.
psychometric testing, in addition to more aggressive control of constipation and other factors that may precipitate encephalopathy.

Conflict of interest statement: none declared.

References
1. Zhang L, Duan YY, Li JM et al. Hemodynamic features of Doppler ultrasonography in patients with portal hypertension: intraoperative direct measurement of portal pressure in the portal venous system. J Ultrasound Med 2007;26:1689–96.
2. Sanyal AJ, Bosch J, Blei A et al. Portal hypertension and its complications. Gastroenterology 2008;134:1715–28.
3. Baik SK. Haemodynamic evaluation by Doppler ultrasonography in patients with portal hypertension: a review. Liver Int 2010;30:1403–13.
4. Schneider AW, Kalk JF, Klein CP. Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. J Hepatol 1999;30:876–81.
5. Kawanaka H, Kinjo N, Anegawa G et al. Abnormality of the hepatic vein waveforms in cirrhotic patients with portal hypertension and its prognostic implications. J Gastroenterol Hepatol 2008;23:129–36.
6. Vilstrup H, Amodio P, Bajaj J et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715–35.
7. Stewart CA, Malinchoc M, Kim WR et al. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl 2007;13:1366–71.
8. Sundaram V and Shaikh OS. Hepatic encephalopathy: pathophysiology and emerging therapies. Med Clin North Am 2009;93:819–36, vii.
9. McPhail MJ, Bajaj JS, Thomas HC et al. Pathogenesis and diagnosis of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2010;4:365–78.
10. Ferenci P, Lockwood A, Mullen K et al. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716–21.
11. Blendis L and Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001;89:221–31.
12. Niederau C, Sonnenberg A, Muller JE et al. Sonographic measurements of the normal liver, spleen, pancreas, and portal vein. Radiology 1983;149:537–40.
13. Sirigos O, Bolondi L, Gaiani S et al. The relationship of endoscopy, portal Doppler ultrasound flowmetry, and clinical and biochemical tests in cirrhosis. J Hepatol 1994;20:11–18.
14. Shen L, Li JQ, Zeng MD et al. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol 2006;12:1292–5.
15. Ilipopoulos P, Vlychou M, Margaritis V et al. Gray and color Doppler ultrasonography in differentiation between chronic viral hepatitis and compensated early stage cirrhosis. J Gastrointestin Liver Dis 2007;16:279–86.
16. Wachsberg RH, Bahramipour P, Sofocleous CT et al. Hepatofugal flow in the portal venous system: pathophysiology, imaging findings, and diagnostic pitfalls. Radiographics 2002;22:123–40.
17. Chawla Y, Santa N, Dhiman RK et al. Portal hemodynamics by duplex Doppler sonography in different grades of cirrhosis. Dig Dis Sci 1998;43:354–7.
18. Gaiani S, Bolondi L, Li Bassi S et al. Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis. Clinical and endoscopic correlation in 228 patients. Gastroenterology 1991;100:160–7.
19. Bryce TJ, Yeh BM, Qayyum A et al. CT signs of hepatofugal portal venous flow in patients with cirrhosis. AJR Am J Roentgenol 2003;181:1629–33.
20. Riggio O, Efrati C, Catalano C et al. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology 2005;42:1158–65.
21. Lam KC, Juttner HU, Reynolds TB. Spontaneous portosystemic shunt: relationship to spontaneous encephalopathy and gastrointestinal hemorrhage. Dig Dis Sci 1981;26:946–52.